MedTrace Logo

The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis

NCT05712343 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-07-12

No results posted yet for this study

Summary

The experiment outlined in this proposal is designed to test the hypothesis that herpesvirus suppression by the systemic anti-herpesvirus valacyclovir (Valtrex) can significantly help to arrest the progressive course of severe marginal periodontitis in adult patients. A prospective, randomized, placebo-controlled, double-blind, clinical trial is employed to test this hypothesis.

Conditions

  • Severe Periodontitis

Interventions

DRUG

Valacyclovir group

The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)

OTHER

Control group

The control group will receive placebo medication, three times a day for 3 days.

Sponsors & Collaborators

Principal Investigators

  • Mike Sabeti, DDS · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-25
Primary Completion
2024-03-01
Completion
2024-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05712343 on ClinicalTrials.gov